Dr Reddy’s receives two USFDA observations for New York API facility

Dr. Reddy’s Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these concerns within the given timeframe.

More From Author

<div>Virat Kohli Gets Annoyed At ‘RCB Team Song’ During Training, Claims Report. Reason Is…</div>

Russia, China Sign Agreement To Build Nuclear Power Station On Moon

Leave a Reply

Your email address will not be published. Required fields are marked *